Innovative Drug Payment Sustainability

Definition

Innovative drug payment sustainability is the system problem of making clinically valuable new medicines affordable while preserving enough return to fund risky, long-duration research and development.

Current Synthesis

VOL.172谭博士/大白牛/小龙：国产创新药到底是真趋势还是虚火？ASCO大会一手现场直击 rejects a one-party solution. Low prices can expand access but can also limit reinvestment; high prices can support R&D yet exclude patients. The episode therefore argues for layered public insurance, commercial insurance, company pricing, and overseas revenue rather than asking patients or drug companies alone to absorb the contradiction.

Key Claims

• Approval does not create access unless patients or payers can finance treatment.
• Persistent price compression can weaken the cash available for future high-risk R&D.
• High innovation returns are not socially useful when treatment remains inaccessible to most eligible patients.
• Layered public and commercial insurance can separate basic protection from optional higher-cost coverage.
• Overseas markets can expand the revenue pool, but globalization introduces clinical, regulatory, partnership, and commercialization demands.

Evidence

• Domestic payment gap - VOL.172谭博士/大白牛/小龙：国产创新药到底是真趋势还是虚火？ASCO大会一手现场直击 attributes China’s lower innovative-drug sales share partly to weaker payment capacity.
• Price tradeoff - VOL.172谭博士/大白牛/小龙：国产创新药到底是真趋势还是虚火？ASCO大会一手现场直击 contrasts lower Chinese prices with higher U.S. prices to explain both access and R&D-recovery pressures.
• Layered coverage - VOL.172谭博士/大白牛/小龙：国产创新药到底是真趋势还是虚火？ASCO大会一手现场直击 proposes commercial insurance and broader social participation rather than assigning the entire affordability problem to pharmaceutical companies.
• Global route - VOL.172谭博士/大白牛/小龙：国产创新药到底是真趋势还是虚火？ASCO大会一手现场直击 connects domestic payment limits with licensing and development in the United States and Europe.

Counterevidence & Qualifications

The source provides speaker-reported cross-country price, spending, and sales-share comparisons without primary datasets. More payment does not guarantee high-value innovation, and insurance expansion can still leave coverage, evidence, bargaining, and equity problems unresolved.

What Changed

• Established affordability and innovation funding as a joint system constraint rather than a simple low-price-versus-high-price choice.

Related Concepts

• Innovative Drug Commercial Insurance Catalog - specific Chinese policy channel for commercial-insurance coverage.
• Healthcare Payer Horizon Mismatch - payer time horizons can diverge from long-term treatment value.
• China Biotech Globalization - overseas revenue is one response to a constrained domestic payment pool.
• Innovative Drug Clinical Benefit Threshold - sustainable payment should follow meaningful clinical value.